Shares of Onconova Therapeutics Inc. (NASDAQ:ONTX) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 1-year consensus target price of $6.00 for the company, according to Zacks. Zacks has also given Onconova Therapeutics an industry rank of 108 out of 265 based on the ratings given to related companies.

Separately, Maxim Group restated a “buy” rating and issued a $6.00 price target on shares of Onconova Therapeutics in a research report on Monday, September 26th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

An institutional investor recently raised its position in Onconova Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Onconova Therapeutics Inc. (NASDAQ:ONTX) by 86.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 280,704 shares of the biopharmaceutical company’s stock after buying an additional 130,404 shares during the period. Renaissance Technologies LLC owned about 1.13% of Onconova Therapeutics worth $163,000 at the end of the most recent reporting period. 2.36% of the stock is owned by institutional investors and hedge funds.

Shares of Onconova Therapeutics (NASDAQ:ONTX) traded up 0.7396% on Tuesday, reaching $2.6696. 14,801 shares of the company were exchanged. Onconova Therapeutics has a 52 week low of $2.50 and a 52 week high of $18.90. The company’s market capitalization is $16.93 million. The company’s 50-day moving average is $2.88 and its 200-day moving average is $4.19.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter. Onconova Therapeutics had a negative return on equity of 256.32% and a negative net margin of 102.42%. The business earned $2.25 million during the quarter. On average, equities analysts expect that Onconova Therapeutics will post ($2.15) EPS for the current fiscal year.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

5 Day Chart for NASDAQ:ONTX

Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with's FREE daily email newsletter.